Evidence map›Paper›PMID 35909973›Full record

ArticleFrontiers in cellular and infection microbiology2022

Novel Lateral Flow-Based Assay for Simple and Visual Detection of SARS-CoV-2 Mutations.

Julien Gomez-Martinez, Steven Henry, Edouard Tuaillon, Philippe Van de Perre, Chantal Fournier-Wirth, Vincent Foulongne, Jean-Charles Brès

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Optical lateral flow assays in early diagnosis of SARS-CoV-2 infection.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Julien Gomez-MartinezPathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Etablissement français du sang, INSERM, University of Antilles, Montpellier, France.
Steven HenryPathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Etablissement français du sang, INSERM, University of Antilles, Montpellier, France.
Edouard TuaillonPathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Etablissement français du sang, INSERM, University of Antilles, Montpellier, France.
Philippe Van de PerrePathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Etablissement français du sang, INSERM, University of Antilles, Montpellier, France.
Chantal Fournier-WirthPathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Etablissement français du sang, INSERM, University of Antilles, Montpellier, France.
Vincent FoulongnePathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Etablissement français du sang, INSERM, University of Antilles, Montpellier, France.
Jean-Charles BrèsPathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Etablissement français du sang, INSERM, University of Antilles, Montpellier, France.
Inserm · FRUniversité de Montpellier · FRCentre Hospitalier Universitaire de Montpellier · FRÉtablissement Français du Sang · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identification of the main SARS-CoV-2 variants in real time is of interest to control the virus and to rapidly devise appropriate public health responses. The RT-qPCR is currently considered to be the reference method to screen SARS-CoV-2 mutations, but it has some limitations. The multiplexing capability is limited when the number of markers to detect increases. Moreover, the performance of this allele-specific method may be impacted in the presence of new mutations. Herein, we present a proof-of-concept study of a simple molecular assay to detect key SARS-CoV-2 mutations. The innovative features of the assay are the multiplex asymmetric one-step RT-PCR amplification covering different regions of SARS-CoV-2 S gene and the visual detection of mutations on a lateral flow DNA microarray. Three kits (Kit 1: N501Y, E484K; Kit 2: L452R, E484K/Q; Kit 3: K417N, L452R, E484K/Q/A) were developed to match recommendations for surveillance of SARS-CoV-2 variants between January and December 2021. The clinical performance was assessed using RNA extracts from 113 SARS-CoV-2-positive samples with cycle thresholds <30, and results demonstrated that our assay allows specific and sensitive detection of mutations, with a performance comparable to that of RT-qPCR. The VAR-CoV assay detected four SARS-CoV-2 targets and achieved specific and sensitive screening of spike mutations associated with the main variants of concern, with a performance comparable to that of RT-qPCR. With well-defined virus sequences, this assay can be rapidly adapted to other emerging mutations; it is a promising tool for variant surveillance.

Indexed as

COVID-19SARS-CoV-2HumansMutationDNA microarraylateral flow strip (LFS)molecular diagnosticSARS-CoV-2 mutationsvisual detection

Identifiers

PMID35909973
PMCPMC9329616
OpenAlexW4285390749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.